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Abstract 
Ovarian cancer is the most gynecological cancer, it has a 5-year mortality rate greater 
than 70%. When ovarian cancer patients undergo chemotherapy their gene expression 
changes. This project is studying a particular group of genes called Fibroblast Growth 
Factors (FGFs), which have been found to be very important in cancer. The hypothesis 
predicted that significant changes in the expression of FGF proteins are associated with 
the development of drug resistance in ovarian cancer. Previous work developed three 
resistant cell lines from the A2780 ovarian cancer cell line (A2780CBN, A2780DXL, 
A2780CBNDXL), In the previous studies, microarray analysis was performed to find 
changes in gene expression in the three cell lines. We have been able to confirm some of 
the changes that indicated a possible role for FGF gene expression changes in drug 
resistance. However, we could only confirm a change in protein expression for one of the 
FGF factors, FGF23, which was altered in A2780CBN and A2780CBNDXL resistant cell 
lines. 
  
  
 iv 
Acknowledgment 
First of all, my deepest acknowledgement goes to my thesis supervisor, Dr. Carita Lanner 
for her understanding, patience and mentoring me step by step through the whole 
research process and for pushing me further than I thought I could go. To my supervisory 
committee, Dr. Amadeo Parissenti and Dr. Mazen Saleh, I am extremely grateful for your 
assistance and suggestions throughout my project.   
 
      My mother, father, thanks for your support and unconditional love. Even though I am 
thousand of miles away, you were always there whenever I needed you. Thank you both 
for helping me survive all the stress and not letting me give up. I love you! 
 
      This thesis would have never been possible without my loving husband 
Abdulrahman.You were always around at times I thought that it is impossible to 
continue, you helped me to keep things in perspective; you are a wonderful man and I am 
truly blessed to share my life with you. I must give special thanks to you. 
 
     My lovely children Aseel and Basel, I owe you lots and lots of fun hours. I couldn’t 
imagine doing my master's degrees without you; you really gave me the reason to 
continue. Words would never say how grateful I am to both of you. 
  
  
 v 
Table of contents 
 
Thesis abstract  iii 
Acknowledgements iv 
Table of contents  
Appendix 
v 
viii 
List of figures x 
List of tables  xii 
  
Introduction    1 
Ovarian cancer  1 
Incidence- mortality rates 1 
Subtypes (histopathology, markers and chemo response) 2 
Treatment (surgery, chemotherapy) 4 
Platinating agents – mechanisms of action          5 
Taxenes agents – mechanisms of action          6 
Platinating agents – mechanisms of resistance         7 
Taxenes agents – mechanisms of resistance          9 
Model System to study drug resistance 10 
 System developed for single and dual agent resistance 11 
 Microarray analysis of cell lines 12 
Functional Interaction Network Analysis 12 
Fibroblast Growth Factors 17 
  
 vi 
Normal role of FGF factors 17 
FGF signaling pathway 21 
 FGF ligand and FGF interactions 21 
 Role of FGF in cancer 24 
Hypothesis and objectives 25 
  
Materials and methods 27 
Cell culture 27 
RNA extraction and analysis 27 
Quantitative polymerase chain reaction (QPCR)   29 
  - cDNA preparation 29 
- Real- time PCR (QPCR) reaction 31 
Western blot analysis 33 
Small interfering siRNA gene knockdown  34 
  
Result 36 
QPCR confirmation of expression in FGF23 factor 36 
Immunoblots to confirm protein expression of FGF23  54 
- immunoblots using cell lysate 54 
- immunoblots of culture supernatant  60 
Small interfering RNA (siRNA) to knockdown FGF23 63 
- Block-IT transfection experiment  65 
Discussion 80 
  
 vii 
Conclusion 88 
Future directions 88 
Reference 90 
Appendices 96 
 
  
  
 viii 
Appendices 
Appendix 1  
Figure 1- 24 hr 10 nM  Block-iT transfections in RPMI 10% FBS no anti-biotic, A2780 cells  
 
99 
Figure 2 - 24 hr 50 nM  Block-iT transfections in RPMI 10% FBS no anti-biotic, A2780 cells  99 
Figure 3 - 24 hr 100 nM  Block-iT transfections in RPMI 10% FBS no anti-biotic, A2780 cells  99 
Figure 4 - 24 hr 10 nM  Block-iT transfections in RPMI 10% FBS no anti-biotic, A2780 cells  100 
Figure 5 - 24 hr 50 nM  Block-iT transfections in RPMI 10% FBS no anti-biotic, A2780 cells  100 
Figure 6 - 24 hr 100 nM  Block-iT transfections in RPMI 10% FBS no anti-biotic, A2780 cells  100 
Appendix 2 
Figure 1 - 48 hr Control in RPMI 10% FBS no anti-biotic, A2780 cells  1 second FITC exposure  
 
101 
Figure 2 - 48 hr Control in RPMI 10% FBS no anti-biotic, A2780 cells, 5 second FITC exposure  101 
Figure 3 - 48 hr 10 nM  Block-iT transfections in RPMI 10% FBS no anti-biotic, A2780 cells  101 
Figure 4 - 48 hr 10 nM  Block-iT transfections in OPTIMEM no anti-biotic, A2780 cells  102 
Figure 5 - 48 hr 50 nM  Block-iT transfections in RPMI 10% FBS no anti-biotic, A2780 cells  102 
Figure 6 - 48 hr 50 nM  Block-iT transfections in OPTIMEM no anti-biotic, A2780 cells  102 
Figure 7 - 48 hr 100 nM  Block-iT transfections in RPMI 10% FBS no anti-biotic, A2780 cells  103 
Figure 8 - 48 hr 100 nM  Block-iT transfections in OPTIMEM no anti-biotic, A2780 cells 103 
Figure 9 - 48 hr 10 nM  Block-iT transfections in RPMI 10% FBS no anti-biotic, A2780 cells  103 
Figure 10 - 48 hr 10 nM  Block-iT transfections in OPTIMEM no anti-biotic, A2780 cells  104 
Figure 11 - 48 hr 50 nM  Block-iT transfections in RPMI 10% FBS no anti-biotic, A2780 cells  104 
Figure 12 - 48 hr 50 nM  Block-iT transfections in OPTIMEM no anti-biotic, A2780 cells  104 
Figure 13 - 48 hr 100 nM  Block-iT transfections in RPMI 10% FBS no anti-biotic, A2780 cells  105 
Figure 14 - 48 hr 100 nM  Block-iT transfections in OPTIMEM no anti-biotic, A2780 cells  105 
Appendix 3 
Figure 1 - 72 hr Control in RPMI 10% FBS no anti-biotic, A2780 cells  1 second FITC exposure  
 
105 
Figure 2 - 72 hr Control in RPMI 10% FBS no anti-biotic, A2780 cells, 5 second FITC exposure  106 
Figure 3 - 72 hr 10 nM  Block-iT transfections in RPMI 10% FBS no anti-biotic, A2780 cells  106 
  
 ix 
Figure 4 - 72 hr 50 nM  Block-iT transfections in RPMI 10% FBS no anti-biotic, A2780 cells  106 
Figure 5 - 72 hr 100 nM  Block-iT transfections in RPMI 10% FBS no anti-biotic, A2780 cells  107 
Figure 6 - 72 hr 10 nM  Block-iT transfections in RPMI 10% FBS no anti-biotic, A2780 cells  107 
Figure 7 - 72 hr 50 nM  Block-iT transfections in RPMI 10% FBS no anti-biotic, A2780 cells  107 
Figure 8 - 72 hr 100 nM  Block-iT transfections in RPMI 10% FBS no anti-biotic, A2780 cells 108 
 
  
  
 x 
List of Figures 
 
Figure1: Representation of A2780CBN cluster 14 
Figure2: Representation of A2780DXL cluster 15 
Figure 3: Representation of A2780CBNDXL cluster 16 
Figure 4: Splicing diagram showing the origins of the two main structural 
isoforms of the FGF. 
20 
Figure 5: QPCR analysis of FGF1 expression in the A2780 parent and resistant 
cell lines 
 
39 
Figure 6:  QPCR analysis of FGF2 expression in the A2780 parent and resistant 
cell lines 
 
41 
Figure 7: QPCR analysis of FGF18 expression in the A2780 parent and resistant 
cell lines 
 
44 
Figure 8: QPCR analysis of FGF20 expression in the A2780 parent and resistant 
cell lines 
 
46 
Figure 9: QPCR analysis of FGF23 expression in the A2780 parent and resistant 
cell lines 
 
48 
Figure 10: QPCR analysis of FGFR1b expression in the A2780 parent and 
resistant cell lines 
 
50 
Figure 11 A, B, C: QPCR analysis of FGFR1c, FGFR2b and FGFR2c expression 
in the A2780 parent and resistant cell lines  
 
52 
Figure 12: QPCR analysis of FGFR3 expression in the A2780 parent and 
resistant cell lines 
 
53 
Figure 13: FGF18 immunoblot of protein lysates from the A2780 parent and 
resistant cell lines 
 
55 
Figure 14: FGF20 immunoblot of protein lysates from the A2780 parent and 
resistant cell lines 
 
57 
Figure 15: FGF23 immunoblot of protein lysates from the A2780 parent and 
resistant cell lines 
59 
  
 xi 
 
Figure16: Culture medium immunoblots for FGF18, FGF20 and FGF23 61 
  Figure 17: QPCR analysis for siRNA transfection for 24 hr GAPDH knockdown 
 
64 
Figure 18: QPCR analysis for siRNA transfection for 48 hr GAPDH knockdown 
 
66 
Figure 19: QPCR analysis for siRNA transfection for 48 hr GAPDH knockdown 70 
Figure 20: QPCR analysis for siRNA transfection for 48 hr single FGF23 
knockdown 
 
72 
Figure 21: QPCR analysis for siRNA transfection for 48 hr single FGF23 
knockdown 
 
75 
Figure 22: QPCR analysis for siRNA transfection for 48 hr single FGF23 
knockdown 
 
76 
Figure 23: QPCR analysis for siRNA transfection for 48 hr pooled FGF23 
knockdown 
78 
  
  
 xii 
 
List of Tables 
 
Table 1: The interaction between FGF ligands and FGFR1-3 
 
23 
Table 2: cDNA Master Mix from the kit reagents 
 
30 
Table 3: Primers used to amplify FGF target genes 
 
32 
Table 4: Microarray fold changes in expression of FGF genes in the A2780CBN, 
A2780DXL, and A2780CBNDXL lines compared to A2780 
 
37 
Table 5: Comparison of the microarray results with the QPCR results 
 
Table 6: 24 hr GAPDH fold changes values and the P values based on the QPCR 
analysis 
 
 
Table 7: 48 hr GAPDH fold changes values and the P values based on the QPCR 
analysis 
 
 
39 
64 
 
66 
 
Table 8: Transfection efficiency for the Block-IT transfections with variant 
conditions 
 
68 
Table 9: GAPDH fold changes values and the P values based on the QPCR 
analysis 
 
70 
Table 10: Single FGF23 siRNA fold changes values and the P values based on the 
QPCR analysis 
 
73 
Table 11: pooled FGF23 siRNA fold changes values and the P values based on 
the QPCR analysis 
76 
 
  
  
 1 
Introduction 
Ovarian Cancer   
Cancer is a major cause of death in women throughout the world. In Canada, it is 
estimated that 76 000 deaths will be due to cancer in 2014 it is responsible for 30% of all 
deaths[2]. Ovarian cancer is the most lethal gynecological cancer and it is responsible for 
5% of cancer deaths[3] . The reason for the increased mortality is because women who 
have ovarian cancer do not show any early symptoms and early diagnosis has not been 
successful. Symptoms that can be observed in women with ovarian cancer are usually not 
clear, for example unusual bloating, abdominal fullness, pressure, difficulty eating and 
back pain, and these symptoms are vague and obscure [4]. Because of this, more than 
70% of women are diagnosed at late stages [5]. To describe the growth or spread of 
ovarian cancer, there are four stages: I through IV. Staging is very important because 
ovarian cancer has different stages and they are treated differently. Each stage is divided 
into three subtypes except stage four. Stage I refers to ovarian cancer that is located 
inside or associated with the ovaries only. Stage II refers to ovarian cancer that is located 
in one or both ovaries and has spread into the pelvis. Stage III ovarian cancer has grown 
outside the area of the pelvis into the abdominal cavity, also if cancer is found in lymph 
node it is considered to be stage III. Stage IV describes ovarian cancer that has spread 
(metastasized) to distance organs such as the liver and lungs. However if the cancer is 
found only on the surface of organs and not penetrating the organs themselves, the cancer 
is described as stage III.  
Based on the staging criteria, it is not difficult to understand that the five years 
survival rate for women with stage III and stage IV disease is lower than 20% [6].   
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Ovarian cancer is classified into different types. Epithelial ovarian cancer is the most 
common type and accounts for approximately 90% of malignant ovarian tumours [7], and 
these tumours are derived from the surface of the ovarian epithelium. The other two 
ovarian tumour types that are not derived from the epithelum, are stromal and germ cell 
tumours. These tumors are not as common as epithelial-derived tumors. Epithelial 
ovarian cancer is classified based on histopathology which observes changes in the 
tissues caused by the cancer, immunohistochemistry which is the process of detecting 
specific antigens in tissues by staining with antibodies labeled with fluorescent material, 
and molecular analysis which is a method of classifying disease by analyzing DNA or 
RNA transcripts, into high grade-serous, low grade-serous, endometrioid, clear cell and 
mucinous carcinomas [8]. About 70% of deaths are seen in patients with high grade-
serous ovarian carcinomas [9]. 
 High grade serous (HGS) carcinoma is the most common type of ovarian carcinoma 
which accounts for 70% of all cases of ovarian cancer. Mutations in the p53 and BRCA 
1, 2 genes are frequent in high grade serous carcinoma. High grade serous carcinomas are 
the most common in North America. Despite the high mortality rate, high grade serous 
ovarian cancer has an initial 80% response rate to chemotherapy drugs [8, 10]. Although 
HGS ovarian cancer has a  high response rate to  chemotherapy, the mortality rate is still 
high because the majority of women have recurrence of treatment-resistant tumours. 
Low grade serous carcinoma is not as common and accounts for < 5% of the cases 
[8]. It is usually diagnosed at high stage. Genetic abnormalities common to low grade 
serous ovarian cancer are different from high grade serous carcinoma. Approximately 
between 20% to 40% of low grade serous carcinomas have a dysregulation in the KRAS 
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gene, however only 5%  of low grade serous carcinoma have mutaions in the BRAF gene 
[11]. Initial treatment of low-grade serous carcinoma involves surgery and platinum-
based chemotherapy. However, treatment for relapses is secondary cytoreduction, salvage 
chemotherapy or hormone therapy [11] 
Mucinous carcinomas are much less common in ovarian cancer, only 3% of ovarian 
carcinomas are of the mucinous type. It is well known that mucinous carcinomas have a 
poor response rate to chemotherapy. Mutations in KRAS are the most common mutation 
found in mucinous carcinomas. HER2 amplification is also present in mucinous 
carcinomas [8] [12]. 
Endometrioid carcinomas are more common and account for approximately 10% of 
all cases of ovarian cancer. Most are found in stage I or II and need no additional 
treatment after surgery. Higher stages of endometrioid carcinomas are often treated with 
chemotherapy such as carboplatin, paclitaxel and combination chemotherapy of 
carboplatin with paclitaxel [13]. The most common genetic dysregulations in 
endometrioid carcinoma are somatic mutations in CTNNB1, KRAS, ARIDIA and 
PIK3CA. In addition, there are less common mutations, including genes like PTEN, 
PPP2R1A and TP53 [8, 14] . The response rates to treatment have been reported to be 
between 10-15%. 
Clear cell carcinomas present at a similar percentage as endometrioid carcinomas 
which is 10% and they are more common in the Asian population [8, 10]. Clear cell 
carcinoma has a 15% response rate to chemotherapy treatment , demonstrating that this 
type of ovarian cancer does not respond well to chemotherapy. However, it has been 
reported that there are positive effects of combined radiation and chemotherapy[15]. The 
  
 4 
molecular markers of clear cell carcinoma are mutations in ARID1A, PTEN, PIK3CA 
and HNF-1B [16]. 
Besides the type of ovarian cancer, treatment of ovarian tumours depends on the stage 
of cancer. Because most of the disease is diagnosed at a late stage, treatment typically 
involves removal of the bulk of the tumour as the main treatment for most ovarian 
cancers, followed by chemotherapy, which is a drug that is used to kill cancer cells by 
stopping them from growing and dividing. In the 1940’s, alkylating agents were the 
earliest drugs that were used to treat ovarian cancer, including melphalan, ifosfamide and 
chlorambucil [17]. In the 1970’s, platinum agents were found to show more effectiveness 
after alkylating agents [18].  
There are two different methods used to deliver chemotherapy to ovarian cancer 
patients. The first option is to give the patient the drug by the intravenous (iv) route 
which is to deliver the chemotherapy into a vein. The other option, intraperitoneal 
delivery, is to have the chemotherapy delivered directly to the abdominal cavity by using 
a thin tube [19]. In the two different types of administration, the same chemotherapy 
regimens are used (cisplatin-carboplatin and paclitaxel), but the dosing schedule is 
different. Intraperitoneal delivery has a significant improvement in long-term 
progression-free survival (PFS) and overall survival (OS) compared with intravenous 
(IV) chemotherapy [20]. Evidence provided by M. Fung-Kee-Fung et al. suggested a 
significant survival benefit for cisplatin IP chemotherapy in patients with epithelial 
ovarian cancer stage III [21]. Another advantage of intraperitoneal delivery is that higher 
concentrations of drug could be used, in addition to demonstrating a longer half-life of 
drug compared with intravenous route. However, toxicity is more frequent with IP than 
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with IV and the most common symptoms of toxicity are abdominal pain, fatigue and 
metabolic toxicities [22].  
Unfortunately, chemotherapy drugs are not only killing cancer cells, they also harm 
healthy cells (cytotoxicity), which causes side effects.  These can occur with any type of 
treatment for ovarian cancer and include symptoms such as nausea and vomiting, loss of 
hair, diarrhea and allergic reactions. 
    Currently, standard chemotherapy for most types and stages of ovarian cancer consists 
of platinating agents and/or taxanes[23]. Many patients achieve complete clinical 
response following the treatment, but often, patients will have a recurrence and present 
with disease after treatment. In addition, they typically develop drug resistance and stop 
responding to the chemotherapy agents [24].  
 
Platinating Agents – Mechanisms of Action    
Platinating agents are drugs that used clinically to treat different types of cancer such 
as head and neck, ovarian, lung and testicular [25] . The chloride ions on the platinum 
drugs are usually replaced by water molecules once they enter the cell. Positively charged 
platinating agents will interact with nucleophilic DNA, forming adducts that change 
DNA structure. Platinating agents react with the N7-atom of guanine or adenine residue. 
Platinating agents form many type of adducts: monoadducts, intrastrand crosslinks and 
interstrand crosslinks. Monoadducts form when the platinating agent binds to only one 
nucleotide, usually adenosine or guanosine. When monoadducts bond again to another 
adenosine or guanosine, most of the monoadducts react further to form crosslinks [25]. 
Intrastrand crosslinks form when the platinating agent binds to two nucleotides  on the 
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same strand of DNA. Most of the crosslinks are intrastrand. Interstrand crosslinks form 
when platinating agent binds to two nucleotides on opposite DNA strands. As a result, 
formation of DNA adduct can induce different cell death pathways. 
 
Platinating agents can also have toxic effects that cause damage to patients’ organs. 
Ototoxicity is present in a high number of patients who received high doses of platinating 
drug [26]. Cisplatin has been found to target cochlear hair cells resulting in damage to 
hearing. The mechanism of action might be the production of reactive oxygen species 
(ROS) that lead to cell death by apoptosis [26]. 
Reactive oxygen species (ROS) is also another mechanism of cisplatin, however the 
detailed mechanism is still unclear. Reactive oxygen species are produced by the 
mitochondria which cause cell death upon exposure to cisplatin. It has been reported that 
DNA integrity, bioenergetics functionality and mitochondrial redox status are important 
inducers of cellular response to cisplatin-induced mitochondrial damage. Moreover, it has 
been shown by Marullo et al. that reactive oxygen species are observed in vivo after 
exposure to cisplatin in several tissues[27].   
 
Taxane Agents – Mechanisms of Action    
Taxanes are cytotoxic drugs that are used as a first line treatment in ovarian cancer. 
Taxanes (paclitaxel) are isolated from the bark of the yew tree. Taxanes include 
paclitaxel and docetaxel. The principal mechanism of action of taxanes is the disruption 
of microtubule depolymerization. Microtubules play an important role in cell division and 
maintaining cell shape. Microtubules are composed of alpha and beta tubulin 
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heterodimers. Taxanes interfere with the depolymerisation of microtubule resulting in 
cell cycle arrest and apoptosis. When a comparison is made between the two most 
commonly used taxanes, docetaxel was found to have 1.9 fold higher affinity for the beta-
tubulin binding site compared to paclitaxel [28].   
Apoptotic pathway induction caused by disruption of microtubule structure via taxane 
drugs is an important mechanism of taxanes. Damage of microtubules by taxanes induces 
Bcl2 protein hyperphosphorylation that plays an important role in regulation of apoptosis. 
Hyperphosphorylation of Bcl2 induces apoptosis.  
Taxanes can also induce Reactive oxygen species (ROS) at a high level which leads 
to apoptosis. Reactive oxygen species can cause significant damage to cells when they 
reach high concentrations. This damage includes DNA damage, protein and lipid 
oxidation, which leads to cell apoptosis [29]. 
 
Ovarian Cancer and Chemotherapy Resistance 
One of the major problems associated with chemotherapy treatment is the 
development of drug resistance. Approximately 70% of the patients undergoing treatment 
for advanced stage tumours will develop recurrent disease [1]. To understand how to 
overcome drug resistance, it is important to understand the mechanisms that play a role in 
the development of chemotherapy drug resistance. 
 
Mechanisms of resistance to Platinating Agents 
The platinating agents most commonly used are cisplatin and carboplatin. These are 
drugs containing platinum which interact with a DNA, RNA and protein functions [25]. 
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Platinating agents target DNA more, compared to other molecules, causing cell cycle 
arrest, apoptosis and signaling DNA damage response [30].  
A major mechanism of resistance to platinating agents is reducing the amount of drug 
entering the cell [25]. Copper transporters are associated with platinating agent 
resistance. The copper transporter CTR1 regulates cisplatin uptake [31]. It has been 
reported that knockdown of CTR1 is associated with decreasing cisplatin uptake by 80% 
in both mouse embryonic fibroblasts and yeast [32, 33]. The other two copper 
transporters that are involved in resistance to cisplatin are ATP7A and ATP7B. 
Deactivation of their transporter activity is linked with decreasing copper efflux from 
cells. It has been reported that overexpression of ATP7A in the 2008 human ovarian 
cancer cell line induced resistance to cisplatin, carboplatin and oxaliplatin. Furthermore, 
high levels of copper efflux transporter ATP7A and ATP7B are linked with a poor 
response in patients with ovarian cancer receiving  cisplatin or carboplatin-based 
chemotherapies[34]. 
DNA repair is also one of the most important mechanisms involved in platinum 
resistance. Nucleotide excision repair is one of the DNA repair pathways that happen 
when a DNA adduct is formed and alter the shape of the DNA helix. This damage is 
excised by the excision repair cross complementation group 1 ( ERCC1) and xeroderma 
pigmentosum complementation group F (XPF) proteins. In the absence of ERCC1 and 
XPF, the DNA will not be repaired leading to cell death[35]. Another pathway that is 
involved in repairing adducts induced by platinating agents is the mismatch repair 
pathway. Mismatch repair occurs when the Mut protein recognizes unmatched DNA base 
pairs caused by platinating agents and induces apoptosis. Therefore, absence of MMR 
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mechanism leads to carboplatin resistance [35, 36]. The study by Fink, D. et al. showed 
an association between loss of the DNA mismatch repair proteins, which recognize the 
DNA damage caused by platinum agents and decreasing level of resistance to drugs [37]. 
 
Mechanisms of resistance to Taxanes 
Taxanes such as docetaxel and paclitaxel stabilize microtubules by stopping 
depolymerisation, which is important for proper continuation of the cell cycle [38]. By 
binding strongly to the β-tubulin subunit of the microtubules, taxanes cause cell cycle 
arrest, which leads to cell death [39]. Resistance to taxanes can occur because of 
increased expression of p-glycoprotein efflux pumps, which is a common mechanism that 
is involved in resistance to taxanes. The P-glycoprotein, ABCB1, is a member of the 
ATP-binding cassette (ABC) transporter family that enables the efflux of many 
anticancer drugs including taxanes [40]. High-level expression of the ABCB1 gene 
results in decreasing the concentration of taxanes. A study done by Ehrlichova et al. [41] 
using human breast cancer cells showed via Reverse Transcription Polymerase Chain 
Reaction (rtPCR) that resistant cells expressed a high level of p-glycoprotein mRNA 
compare to the parental sensitive cell line. Another study by Hembruff, S.L. et al. 
indicates that there is a relationship between the expression of drug transporters in MCF-
7 breast cancer cells and the resistance to docetaxel [42]. 
 
Another mechanism that is involved in resistance to taxanes and has the ability to 
deactivate the drug are cytochrome p450 enzymes. Cytochrome p450 is known to 
metabolize a wide range of anticancer drugs [43]. The CYP1B1gene is a member of the 
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P450 family of cytochromes that are present in many types of malignant tumors and in 
metastatic disease [44]. It has been reported by McFadyen et al. that transfection of 
CYP1B1 leads to increased resistance to docetaxel in V79 cell lines [43]. Another study 
that also was done by McFadyen et al. using the chinese hamster ovary, CHO, cell line 
which expresses cytochrome CYP1B1, exposed the cells to docetaxel. A high increase in 
resistance to docetaxel in the cell line expressing CYP1B1 was observed compared to the 
parental cell line (P= 0.03) [43]. 
Another mechanism of resistance to taxanes is alterations in β-tubulin, either by 
increased expression or by mutation in the gene [45]. Transfection of Chinese hamster 
ovary (CHO) cells were used to determine whether β-tubulin mutations found in cancer 
cells have the ability to induce resistance to taxanes in microtubules. The results showed 
that there were three mutations (A185T, A248V and R306C) which caused paclitaxel 
resistance. This mutations cause alterations in microtubules, induce sensitivity to 
microtubules-disruptive drug and cause deficiency in mitosis[46].     
In general, lack of response to chemotherapy drugs is linked with changes in gene 
expression, and epigenetic changes that affect drug uptake, metabolism of the drug, or 
export of drugs from tumour cells [47]. Because of increased variability from one patient 
to another and the complexity of involvement of the circulatory system, it is difficult to 
understand the main mechanism of resistance for different chemotherapy agents in a 
clinical setting.  
 
Model Systems to Study Drug Resistance 
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Several in vitro and in vivo cancer models have been developed from cancer cell 
lines to study the mechanisms of drug resistance that affect cancer treatment. There are 
limitations of using in vitro models such as lack of a diverse cell population as observed 
in patient tumours, but in vitro cell culture can provide useful information such as drug 
sensitivity, cell biology and in the identification of signalling pathways that are affected 
by drug exposure [48].  
To understand how drug resistance plays a very important role in the development of 
chemotherapy resistance in ovarian cancer, researchers have developed resistant cell lines 
by selecting for cells that are able to grow in the presence of increasing chemotherapy 
drug concentrations [49]. In the clinical setting, ovarian cancer patients are often treated 
with carboplatin together with paclitaxel, although docetaxel is also used as an alternative 
to paclitaxel because of reduced toxicity but similar effectiveness [50]. To understand 
how this dual agent chemotherapy, used for treatment of advanced ovarian cancer, is also 
able to cause development of resistance in patients, our research group has developed 
several drug resistant ovarian cancer models based on the A2780 cell line [1]. Our group 
has developed cell lines resistant to single agents, such as carboplatin (A2780CBN) and 
docetaxel (A2780DXL), in addition to a dual agent resistant cell line, the 
A2780CBNDXL line. Resistant cell lines were established by propagating cells in media 
containing increasing concentrations of carboplatin alone, docetaxel alone or in the 
presence of both carboplatin and docetaxel. Armstrong et al., demonstrated that cells 
exposed to combination chemotherapy showed distinct genetic alterations, compared to 
gene expression changes seen in the single agent resistant cell lines.  Armstrong et al. 
used microarray analysis, which is a widely used genomic tool that allows for profiling of 
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mRNA expression of thousands of genes at once to identify changes in gene expression 
associated with drug resistance [51].   
cDNA microarray analysis uses an array of thousands of microscopic spots of 
oligonucleotides of specific DNA sequences arranged on slides to which cDNA sequence 
of samples can hybridize [52]. To perform the microarray analysis, total RNA is 
extracted from cells, which is then used to generate cDNA using reverse transcription. 
cRNA is then generated which is labelled using a dye before applying the sample to the 
array. As a result, strength of the hybridization signal produced is because of the gene 
expression level of that particular gene [53].  
Using this technique, thousands of gene expression changes were identified in the 
resistant cell lines when compared to the parental A2780 line. The microarray results 
showed significant changes in 3000 genes in the A2780CBN line, 4621 genes in the 
A2780DXL line and 4070 genes in the A2780CBNDXL line [1]. More analysis of the 
data and comparison between the three drug resistant cell lines showed the resistance 
seen in combination chemotherapy is not a combination of changes identified in the 
single agent resistant lines. Greater than 70 % of the total gene expression change was 
found to be unique to the A2780CBNDXL cell line [1]. The gene expression data 
obtained using the microarray experiments were further analyzed using Functional 
Interaction Network Analysis. 
 
Functional Interaction Network analysis 
 Microarray generates thousands of different gene expression changes, but other 
analysis methods are needed to organize the observed changes to help identify pathways 
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affected by the genes. Therefore pathway analysis can be performed which identifies 
interactions between different genes or proteins to identify the pathways affected [54].  
 
Previous work that was done in our lab performed microarray analysis to find changes in 
gene expression in the three cell lines that were developed from the A2780 ovarian 
cancer cell line. The microarray results were used to perform Functional Interaction 
Network (FIN) analysis, which was carried out by Dr. Irina Kalatskaya at the Ontario 
Institute for Cancer Research (OICR). 
 
A FIN based analysis was performed on microarray data to identify genes that play a role 
in drug resistance. Genes with significantly different expression were included into the 
functional interaction network analysis. Linkers were identified between genes to connect 
them in one subnetwork using a minimum spanning tree algorithm, which automatically 
identifies gene clusters that define a signaling pathway.  
      Each of the three cell lines has several clusters that come up as significant. For 
example, there are significant clusters present in A2780CBN such as (cadherin, ECM, 
FGF and RhoGTPases) (Figure1) and in A2780DXL (TNF, GPCR, TGF and cell cycle) 
(Figure 2) whereas A2780CBNDXL which has the biggest number of clusters (collagen, 
P-glycoprotein, FGF and cadherin) (Figure 3).   
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Figure1: Representation of A2780CBN cluster: there are several 
clusters that are significant in A2780CBN.  
                            Carboplatin (CBN) cluster 
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Figure2: Representation of A2780DXL cluster: there are several 
clusters that are significant in A2780DXL.  
                            Docetaxel (DXL) cluster 
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Figure 3: Representation of A2780CBNDXL cluster: there are 
several clusters that are significant in A2780CBNDXL.  
                            Dual (CBNDXL) cluster 
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To determine protein network validity we selected promising clusters from each cell line 
for validation which is the Fibroblast Growth Factor (FGF) cluster. There are several 
reasons for selecting the FGF clusters, which include the fact that the FGF cluster was 
present in the functional network analysis for each cell line and that the biggest cluster 
was found in the A2780CBNDXL. The microarray analysis had shown the greatest 
number of changes was in the A2780CBNDXL cell line, so the large FGF cluster in this 
cell line seemed to validate the microarray results. In addition, changes in the expression 
of FGF proteins are common in many types of cancers, some of which may play an 
important role in drug resistance. Moreover it is well-known that FGF proteins are altered 
in ovarian cancer. 
 
Fibroblast Growth Factors 
 
Normal role of FGF factors 
Fibroblast growth factors (FGFs) play a fundamental role in developmental processes. 
During embryonic development FGFs are found to be important in many aspects such as 
regulating cell proliferation, migration and differentiation. In adult life, FGFs are crucial 
for tissue repair. 
       The human FGF family is a large family consisting of 22 members (FGF-1 to 14 and 
FGF-16 to 23). The FGF family is divided into six subfamilies depending on 
phylogenetic analysis and similarities in sequence: FGF1 and FGF2, the FGF3 family 
(FGF3, FGF7, FGF10, FGF22), the FGF4 family (FGF4, FGF5, FGF6), the FGF8 family 
(FGF8, FGF17, FGF18), the FGF9 family (FGF9, FGF16, FGF20) and the FGF19 family 
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(FGF19, FGF21, FGF23). An additional group, the FGF11 subfamily (FGF11, FGF12, 
FGF13, FGF14) is not considered to be a true member of the FGF family, despite 
sequence similarity to the FGF factors, because the FGF11 subfamily regulates voltage-
gated sodium channels and does not bind to FGF receptors. To indicate this difference, 
the FGF11 subfamily are called fibroblast homologous factors (FHF) [55]. All the FGF 
growth factors, except FGF1, FGF2, and the FGF-9 subfamily, have signal peptides 
which allow the proteins to be released outside the cells. Cellular production of the FGF9, 
FGF16, and FGF20 subfamilies are through the endoplasmic reticulum (ER) – Golgi 
secretory pathway, whereas the FGF1 and FGF2 subfamily are produced in the cytoplasm 
[56]. The FGF proteins can be divided into groups as having paracrine effects which 
targets cells that are close to the cells producing the hormones and affects cells of a 
different type (FGF1, FGF2, FGF4, FGF8 and FGF9 subfamilies).  FGF factors with 
endocrine effects are hormones that enter the blood circulation directly and travel to 
distant target organs (FGF19 subfamily) while intracrine FGF proteins act inside cells 
(FGF11-14). Paracrine and endocrine FGFs act through cell-surface FGF receptors 
(FGFRs) [57]. 
Fibroblast growth factors (FGFs) bind fibroblast growth factor receptors (FGFRs) which 
are tyrosine kinase receptors. There are 7 main FGFR isoforms (FGFR1b, FGFR1c, 
FGFR2b, FGFR2c, FGFR3b, FGFR3c and FGFR4). The b and c isoforms are 
alternatively spliced isoforms which are tissue specific. The b isoforms are expressed in 
epithelial tissues while the c isoforms are expressed in mesenchymal tissues. FGF 
receptors are composed of three important structures: extracellular immunoglobulin 
domains (D1-D3), a single transmembrane domain and a cytoplasmic tyrosine kinase 
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domain (Figure 1). There is also an acid box region, located between the D1 and D2 
domains which plays an important role in receptor autoinhibition. The D3 domain is 
important for determining ligand specificity of the FGFR. Alternative splicing of the D3 
domain can form the b and c isoforms of FGFR1, FGFR2 and FGFR3. (Figure 4) [55] 
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Figure 4:  The two main structures isoforms of (FGFRs1-3), the alternative splicing of (b 
and c) are produced in the second half of D3 domain region [58].  
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FGF signaling pathways 
When FGF: FGFR bind to each other, it will cause dimerization of two FGFRs and the 
activation of the intracellular kinase domain. Activation of the kinase domain occurs 
through transphosphorylation of the paired kinase domains. Other important activation 
changes are phosphorylation of the c-terminal ends of the receptors, phosphorylation of 
the juxtamembrane region and kinase insert. There are two main FGF signaling pathways 
which are the phospholipase C gamma (PLC-γ) (also called FRS1) and the FGFR 
substrate 2 (FRS2) pathway. 
         PLC-γ pathway activation requires tyrosine 766 (y766) in the FGFR, located at the 
C-terminal end of FGFR, to be autophosphorylated. PLC-γ can bind to the 
phosphorylated tyrosine through its SH2 domains. This activation leads to hydrolysis of 
phosphatidyl-4,5-bisphosphate (PIP2), producing inositol triphosphate (IP3) and 
diacylglycerol (DAG) which leads to activation of protein kinase C (PKC). In the second 
important signaling pathway, the docking protein FRS2 binds to the juxtamembrane 
region of FGFR. Activation of a FGFR leads to phosphorylation of FRS2 which allows 
the adaptor proteins Grb2 and the protein tyrosine phosphatase, Shp2, to bind FRS2. The 
recruitment of the Grb2 and Shp2 proteins leads to formation of complexes with more 
Grb2 molecules and the son of sevenless (SOS) which eventually activate RAS, RAF and 
MEK resulting in activation of the mitogen-activated protein kinase (MAPK) pathway 
and the phosphatidylinositol 3-kinase –AKt (PI3K-Akt) signaling pathway.  
 
FGF ligand and FGFR interactions 
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Interactions between FGF ligands and heparin or heparan sulfate (HS) proteoglycan 
(HSPG) in the extracellular matrix is essential for stabilizing FGF proteins and limiting 
their diffusion [59]. The interaction with heparin/heparin sulfate is also important for 
stabilizing the binding of the FGF ligands with their receptors. 
         Each FGF can bind to several different FGFR subtypes. FGF1 has the ability to 
bind all the FGFR subtypes (FGFR1, 2, 3, 4) while the other FGF factors bind to some of 
the receptor subtypes but not all [60]. For example, FGF3 and FGF7 bind to FGFR1, 
FGFR2 and FGFR3 but not FGFR4 [61].   
        In addition, each FGF receptor subtype can exist as two isoforms, the b and c 
isoforms. These isoforms are produced via alternative splicing of the transcripts. The 
isoforms are tissue specific in that the b isoforms are expressed in epithelial tissues while 
the c isoforms are expressed in mesenchymal tissues (Table 1). Only FGF1 can bind to 
both b and c isoforms of any receptor. The other FGF factors typically bind to either an 
epithelial isoform or the mesenchymal isoform of each receptor there are some 
exceptions to this, for example, the FGF4 ligand family can bind to both the b and c 
isoforms of FGFR1.  
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Table 1: The interaction between FGF ligands and FGFR1-3. The designations of 
b and c represent the alternative splicing of FGFR. The b isoform is expressed in 
epithelial tissue and the c isoform is expressed in mesenchymal tissue) 
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The role of FGF in cancer 
Deregulation of FGFR signaling is associated with many human cancers. In cancer, 
FGFR have been found to become over activated by several mechanisms, including gene 
amplification, chromosomal translocation and mutations. FGFR alterations are detected 
in a variety of human cancers, such as breast, bladder, prostate, ovarian, endometrial and 
lung cancers. For example, the mutation Gly388Arg in FGFR4 has been found to be 
associated with breast and colorectal cancer [62]. The same mutation, Gly388Arg, is also 
associated with progression of human prostate cancer [63]. Another interesting example 
is that SNPs (single-nucleotide polymorphisms) within intron 2 in FGFR2 have been 
found to be associated with breast cancer [64]. In FGFR3 there were three somatic 
mutations in (G380/382R; K650/652M and K650/652T) that are associated with bladder 
cancer [65].  
In ovarian cancer, mutations (SNPs) in the FGF2 gene may alter angiogenic 
potential which leads to the growth of serous ovarian cancer [66].  
Besides FGF2, other forms of FGF have been found to be associated with ovarian 
cancer. For example, around 40% of ovarian endometrioid adenocarcinomas have 
constitutive activation of Wnt signaling associated with an oncogenic mutation in the 
beta-catenin protein and increased downstream FGF9 expression [67]. FGF9 was found 
to be both mitogenic and to stimulate cell invasion through matrigel in epithelial cell 
types. Amplification of chromosomal region 5q31-5q35.3, which is the most significant 
copy number abnormality associated with serous ovarian cancer, leads to over expression 
of FGF18 [68]. The overexpression of FGF18 caused migration, invasion, and 
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tumorigenicity of ovarian cancer cells. FGF16 is also another example that stimulates the 
proliferation of human ovarian adenocarcinoma cells (SKOV-3- OAW-42) [69] 
Concerning, FGF23, alteration of serum or plasma FGF23 are involved in ovarian cancer. 
It has been shown that serum or plasma FGF23 concentrations are higher in women with 
advanced-stage epithelial ovarian cancer [70]. 
FGF factors can also play a role in chemotherapeutic drug resistance or 
sensitivity. FGF2 has been found to increase the sensitivity of A2780 and MCF-7 cells to 
cisplatin [71], FGFR4 was also found to be a regulator of drug resistance in colon 
cancer[72].  
 
Hypothesis and objectives 
Fibroblast growth factors (FGFs) are important because they play a role in many types of 
cancer including in ovarian cancer. We have generated three drug resistant cell lines from 
A2780 parental cell line which are resistant to carboplatin (A2780CBN), docetaxel 
(A2780DXL), or a combination of carboplatin and docetaxel (A2780CBNDXL), and by 
using the resistant cell lines we can see if significant changes in expression of FGF 
proteins are contributing to the development of drug resistance in ovarian cancer.  
 
The hypothesis of this study is to see if significant changes in expression of FGF proteins 
contribute to the development of drug resistance in ovarian cancer.  
 
The objectives of this study are to validate changes in FGF/FGFR gene expression in cell 
lines by using QPCR technique to confirm changes in expression detected by microarray 
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analysis and to validate changes in FGF protein expression in the cell lines by Western 
blotting. In addition, I wish to knock down the expression of interesting FGF genes in in 
the A2780 cell line by using the siRNA technique and evaluate the effect of changes in 
expression on drug resistance by clonogenic assay.  
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Materials and Methods 
Cell culture: 
The human ovarian carcinoma cell line A2780 was purchased from the European 
Collection of Cell Cultures (ECACC, Salisbury, UK) and maintained in chemotherapy 
drug-free RPMI-1640 medium with 2 mM glutamine (HyClone, South Logan, Utah, 
USA).  The medium also contained 10% FBS (HyClone, South Logan, Utah, USA), and 
1% penicillin (10 000 I.U./mL)/ streptomycin (10 000µg/mL) solution (HyClone, South 
Logan, Utah, USA).  A2780 cell lines resistant to docetaxel (A2780DXL), carboplatin 
(A2780CBN) and to both docetaxel and carboplatin (A2780CBNDXL) were generated 
by Armstrong et al. [1]. The A2780CBN and A2780DXl cell lines were maintained by 
adding 2.22x10-5M carboplatin and 4.05x10-7M docetaxel respectively, A2780CBNDXL 
cells were maintained by adding 6.07x10-6 M carboplatin and 6.07x10-9 M docetaxel. 
Cells were cultured in T75 flasks in a humidified incubator at 37oC with 5% CO2 and 
were checked microscopically daily to ensure they are healthy and growing as expected.  
 
RNA extraction and analysis 
RNA was purified using miRNeasy Mini Kit from Qiagen Laboratories (Mississauga, 
ON, Canada). The drug resistant A2780 cells were released from the flasks with trypsin 
and then counted using a ViCell counter (Beckman Coulter Inc., Mississauga ON, 
Canada). To count cells, the culture medium was collected and added to a 15 mL conical. 
The tissue culture dish was washed with PBS, which was also collected and added to the 
15 mL conical tube and spun at 500 × g for 5 min to harvest the cells. A volume of 700μl 
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of QIAzol lysis solution was added to the plate and using a cell scraper, cells were gently 
scraped off the bottom of the flask into the lysis solution. Homogenization was done 
using a 20-gauge needle-fitted syringe for 1 minute, or until no clumps were visible. The 
tubes containing the homogenized samples were placed at room temperature (25° C) for 5 
minutes, 140 μl of chloroform was added to the homogenate and vortexed for 15 seconds. 
This was important to induce phase separation. The tube was placed on the benchtop at 
room temperature for 2-3 minutes. At this time the separation of the solutions became 
visible. The sample was centrifuged at 12000 x g at 4° C for 15 minutes, and after 
centrifugation, the sample separated into three distinct phases; one upper colourless, 
aqueous phase containing the RNA; a white interphase containing the DNA; and a lower 
red organic phase containing proteins. The upper aqueous phase was transferred to a new 
collection tube, 525 μL of anhydrous ethanol was added to precipitate the RNA, and 
mixed by pipetting up and down. Following precipitation, 700 μl of the sample was 
pipetted onto a RNeasy spin column that was placed in a 2 ml collection tube and 
centrifuged at 8000 x g for 15 seconds at room temperature. During centrifugation the 
RNA binds to the column membrane. The membrane was washed with 700 μl of the 
washing Buffer RWT, supplied in the miRNeasy mini kit, and centrifuged at 8000 x g for 
15 seconds. The flow-through was discarded, and 500 μl of another washing buffer, 
Buffer RPE, also supplied in the miRNeasy mini kit, was added and centrifuged at 8000 x 
g for 15 seconds. The flow-through was discarded. Another 500 μl of Buffer RPE was 
added, and centrifuged at 8000 x g for 2 minutes. RNA was eluted by adding 50 μL of 
RNase free water to the spin column twice, and 1 µL of RNAase OUT (Invitrogen, 
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Carlsbad, CA, USA) was added to the RNA samples to prevent RNA degradation. The 
quantity of RNA in the above preparations was measured  
using the NanoDrop ND-1000 spectrophotometer (Thermo Fisher Scientific Inc., 
Wilmington, DE, USA). RNA samples were stored at -80oC. 
 
QPCR analysis 
cDNA preparation: 
Gene expression can be quantified by measuring the expression of transcribed mRNA. 
Before mRNA can be quantified by (qPCR), the mRNA needs to be reverse transcribed 
into cDNA. Before, reverse transcription, DNAse treatment (Invitrogen, Carlsbad, CA, 
USA) of RNA was performed using 2μg RNA (use 1μg for cDNA preparation and keep 
1μg in -80 oC), 2μl of 10X DNAse buffer, 2μl of DNAse AMP grade and PCR grade H20 
in a final volume of 20μl. The mixture was incubated for 15 min at room temperature, 
then 2μl of 25 mM EDTA was added to stop DNAse activity, the mixture was heated for 
10 min at 65°C and directly used in cDNA production or stored at -80 °C. For the reverse 
transcription reaction, Superscript Reaction Kit (Invitrogen, Carlsbad, CA, USA) was 
used. A master mix was prepared from the kit reagents as shown in (Table 2).  
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  Table 2: cDNA Master Mix from the kit reagents 
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The reaction mix was incubated for 10 min at 37°C, 2μl of  Moloney Murine Leukemia 
Virus Reverse Transcriptase (MMLV-RT)  (Invitrogen, Carlsbad, CA, USA) was added, 
then incubated for 2 hours at 37°C, followed by heating for 5 min at 95°C to inactivate 
the MMLV-RT enzyme. Samples were stored at -20°C. 
 
Real-Time PCR (Q-PCR) Reaction: 
Real –time quantitative polymerase chain reactions (RT-QPCR) were performed on a 
Chromo4TM System machine (BioRad Laboratories, Inc., Mississauga, ON, Canada).  
Standard curves were prepared by diluting template cDNA four times (0.25x), and 
preparing further serial dilutions by diluting each step two times until a series is 
generated (0.25x, 0.125x, 0.0625x, 0.03125x, 0.015625x, 0.0078125x, 0.00390625x). 
Standard curves were generated for a housekeeping gene (28s rRNA) and for each gene 
being tested. Water was also included in the curves to check for random oligonucleotide 
contamination. 
 Samples were usually diluted 16x (0.0625x) to place their expression in the 
middle of the standard curve. Sometimes samples had to be used at a higher dilution, 
especially when the RNA concentration was low or if gene expression was naturally low.  
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 Table 3: Primers used to amplify FGF target genes   
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NCBI Primer-Blast were used to design primers for the FGF1, FGF2, FGF18, FGF20, 
FGF23, FGFR1c, FGFR3 genes. Consensus coding sequences were found using the 
Ensembl database. Alignments between protein coding transcripts were done in the 
ClustalW program, Consensus coding sequences common to all transcripts were used to 
design primers (Table 3). 
Primers for FGFR1b, FGFR2b and FGFR2c genes were designed by Coutu et al. [73] 
Primers were purchased from (IDT Technologies, Coralville, Iowa, USA) 
 
Western blot analysis  
Cell lysates were prepared from three biological replicate cultures using mammalian 
protein extraction reagent, M-PER (Thermo Scientific, Rockford, IL, USA) lysis buffer 
containing HALT protease inhibitor (Thermo Scientific, Rockford, IL, USA), sodium 
fluoride (50 mM), sodium orthovanadate (0.2 mM),. Cells were collected using 0.25% 
trypsin-EDTA. Cell pellets were washed 3 times in PBS before being lysed with lysis 
buffer. Protein concentration in the lysates was determined using the Pierce BCA Protein 
Assay Kit (Pierce, Rockford, IL, USA).  Cell lysate (20 µg protein per lane) was 
separated by 10% Polyacrylamide gel containing (SDS-PAGE). Proteins were transferred 
to BioTrace PVDF membrane (Life Sciences, Pensacola, FL, USA). Membranes were 
blocked with 5% milk solution in 1× TNE (obtained from a 20× TNE stock made using 
100 mL of 1 M Tris-HCl (pH 7.5), 50 mL of 0.5 M EDTA (pH 8.0), 58.44 g of NaCl, 
H2O to 500 mL) containing 0.1% Tween-20 (FisherBiotech, Thermo Fisher Scientific 
Inc., Waltham, MA, USA) for 1 hour. Primary antibody was diluted in milk and 
incubated with the membrane on a rocker over night at 4 ° C. After washing the 
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membrane for 3× 20 min in 1× TNE, the membrane was incubated with secondary 
antibody (Santa Cruz Biotechnology, Dallas, Texas, USA) diluted in 5% milk for 1 hour 
at room temperature, membranes then were washed for 6× 5 min in 1× TNE, the blots 
were incubated in enhanced chemiluminescence (ECL) reagents (GE health care, 
Mississauga, Ontario, Canada) and exposed to X-ray film (Thermo scientific, 
Mississauga, Ontario, Canada). Primary antibodies were from the following suppliers: 
FGF18 (cat. No ab86571, Abcam, San Francisco, California, USA), FGF20 (cat. No. 
AF2547, R&D Systems, Minneapolis, Minnesota, USA), FGF23 (cat. No. AF2604, R&D 
System, Minneapolis, Minnesota, USA). Secondary antibody suppliers were as follows: 
Goat anti-rabbit (Cat. No.ab97200, Abcam, San Francisco, California, USA), rabbit anti-
goat (Cat. No.401515, CALBIOCHEM, San Diego, California, USA). 
 
Small interfering siRNA gene knockdown experiments 
       In this study, siRNA against FGF23 was used to knock down expression of the 
FGF23 gene. Lipofectamine was used in this study to transfect siRNA into the cells. 
Lipofectamine® 2000 Reagent from InvitrogenTM (Waltham, Massachusetts, USA) was 
used to transfect siRNA into the A2780 cells. In short, cells were grown to about 30-50 % 
confluence. After counting, 300x103 cells were plated per well (3 x 6-well plate) in 1.5ml 
RPMI+10% FBS without antibiotic, cells were incubated at 370C for 24hr. In a 24-well 
plate, siRNA and Lipofectamine® were diluted in serum-free Opti-MEM (Life 
technologies, Carlsbad, California, USA) before being combined and added to the cells. 
Lastly cells were incubated at 37oC, 5% CO2, for 24hr. Following transfection with 
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siRNA, total RNA was prepared from the transfected cells, using the Qiagen RNAeasy 
kit, and successful knockdown of gene expression was confirmed using RT-QPCR. 
Transfections with scrambled siRNA and GAPDH siRNA were used as negative and 
positive controls, respectively. The FGF23 siRNA and GAPDH siRNA were provided 
from Ambion® by Life Technologies.  
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Results 
 
QPCR confirmation of expression in FGF factors 
 
FGF1, FGF2, FGF18, FGF20, FGF23, FGFR1, FGFR2 and FGFR3 were selected based 
on the concurrence between the microarray data and the FIN analysis data that were 
compared to generate the group of FGF factors. These FGF factors were selected to 
confirm the level of change in the expression of the mRNA (Table 4). FGF1, FGF2, 
FGF18 and FGF23 are known to be involved in ovarian cancer [68, 70, 74]. Furthermore, 
FGF18 is involved in the cluster analysis in the A2780CBN and A2780CBNDXL cell 
lines. In the A2780CBN cell line, the expression of FGF18 was down regulated (-3.52) 
fold based on the microarray analysis, but was up regulated in the A2780CBNDXL cell 
line (7.27 fold) compared to the A2780 parental cell line based on the microarray analysis 
result (Table 4). FGF20 is not involved in the cluster analysis but in the microarray 
analysis, it has the biggest change in A2780CBNDXL cell line where it was down 
regulated (-131.53 fold) compared to the A2780 parental cell line. Expression of FGF20 
has been found to be associated with the activation of the Wnt/β-catenin pathway [75]. 
Concerning the FGF receptors, both FGFR1 and FGFR2 have been reported in several 
studies to be involved in resistance to chemotherapy [76]. FGFR1 is also involved in the 
cluster analysis in two cell lines which are A2780CBN and A2780CBNDXL. FGFR3 is 
also involved in the cluster analysis in A2780DXL cell line. 
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Table 4: Microarray fold changes in expression of FGF genes in 
the A2780CBN, A2780DXL, and A2780CBNDXL lines 
compared to A2780. Highlighted numbers indicate FGF genes 
which were also present in FIN result. Values in the table 
represent ratios of fluorescent values from the microarray 
between the parent and each cell lines and were calculated as 
described in Armstrong et al. [1]. Positive numbers mean 
upregulation of gene expression and negative numbers mean 
downregulation of gene expression 
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To investigate the level of expression of FGFs we compared the relative amounts 
of mRNA for each FGF factor in the A2780 resistant cells compared to A2780 parental 
cells using Qualitative Real-time Polymerase Chain Reaction (QPCR). Three biological 
samples were used for each FGF in the QPCR analysis. From the data obtained, for 
FGF1, there was no difference seen between the A2780 parental cells and the A2780 
resistant cells (Figure 5). While the microarray analysis showed no difference in FGF1 
expression between the A2780 parental cells and the A2780CBN resistant cells, the 
QPCR analysis was up regulated with a fold change of (3.1) but a P value for the QPCR 
analysis of 0.12  (Table 5). FGF1 from the microarray analysis also showed no change 
between the A2780 parental cell line and A2780DXL resistant cells. However, the QPCR 
analysis showed up regulation and has fold change of (2.3) (P= 0.48). In addition no 
expression seen in A2780CBNDXL cells in the microarray analysis, whereas the QPCR 
analysis showed (2.2) fold change and P value of (0.45). Based on the three QPCR 
comparisons between the A2780 parental cells and the drug resistant cells, there were no 
significant differences in the expression of FGF1.  
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Table 5: Comparison of the microarray results 
with the QPCR results. The P values are 
calculated for each QPCR analysis comparing a 
resistant line to the parent line. 
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Figure 5: QPCR analysis of FGF1 expression in the A2780 parent and resistant cell 
lines. (A) Shows the QPCR analysis for FGF1. (B) QPCR for the S28 control  in the 
A2780 parent and resistant cell lines. 
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 A similar result was observed for FGF2; there was no difference shown between the 
A2780 parental cells and the three resistant cells (Figure 6, Table 5). From the microarray 
analysis, A2780CBN showed no expression change, whereas the QPCR analysis showed 
a low fold change of 1.3 and P=0.550 (Table 5). In addition, based on the microarray 
analysis, no change in expression was detected in A2780DXL, however the QPCR 
analysis indicated that there was a low expression in FGF2 with a fold change of 1.1 and 
a P value of 0.726. In A2780CBNDXL cells, both analyses indicated that the resistant 
cell lines were down regulated compared to the A2780 parental cell line with a fold 
change of about -2 and a P value of 0.288 (Table 5). Therefore, there were no significant 
changes in expression of FGF2 in any of the resistant A2780 cell lines.  
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Figure 6:  QPCR analysis of FGF2 expression in the A2780 parent and 
resistant cell lines. (A) The QPCR analysis for FGF2 (B) QPCR for he S28 
control in the A2780 parent and resistant cell lines reaction. 
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Although the QPCR did not show any change in expression for FGF1 and FGF2, FGF18 
showed an interesting change obtained from the QPCR analysis. A significant difference 
was seen between the A2780CBN resistant cells and the A2780 parental cells (Figure 7). 
The fold change was -8.9 with a P value of 0.0037 (Table 5). However, the microarray 
analysis showed a smaller fold change of -3.4. In addition, the microarray analysis 
showed no expression change in A2780DXL, whereas in the QPCR analysis there was a 
fold change of -1.8 but with a P value of 0.1293. The microarray analysis in the 
A2780CBNDXL cells showed an up regulation of 7.2 fold compared to A2780 parental 
cells. However, this number was not observed in the QPCR analysis, where only a 1.0 
fold change compared to the parent with a P value of 0.9058. In summary, a significant 
change in FGF18 expression was observed in the A2780CBN cell line, based on QPCR 
analysis, but not in the A2780DXL or A2780CBNDXL cell lines. 
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Figure 7: QPCR analysis of FGF18 expression in the A2780 parent and 
resistant cell lines. (A) QPCR analysis for FGF18 (B) QPCR for the S28 
control in the A2780 parent and resistant cell lines reaction. 
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The data for FGF20 showed the most interesting change based on the QPCR analysis 
(Figure 8). There was a significant down regulation in A2780CBNDXL cells compared 
to A2780 parental cells in both the microarray and QPCR analysis, which have a fold 
change of -131.15 and -135.7 respectively with P= 0.0002 for the QPCR result (Table 5). 
A similar result was also observed in the A2780CBN cells which showed a significant 
difference compared to parental cells in both the microarray and QPCR analysis with a 
fold change of  -67.5 and -68.6 respectively with P= 0.0000197 for the QPCR result 
(Table 5). However, although there was a difference in expression between the 
A2780DXL cells and the A2780 parental cells, it was not significant. The microarray 
result showed a -16.2 fold change, whereas the QPCR analysis showed -6.9 fold change 
with P= 0.0682 (Table 5). Based on these results, there is a significant difference in 
FGF20 expression in both the A2780CBN and A2780CBNDXL cell lines but not in the 
A2780DXL cell line.  
  
 47 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 8: QPCR analysis of FGF20 expression in the A2780 parent and 
resistant cell lines. (A) QPCR analysis for FGF18 (B) QPCR for the S28 
control in the A2780 parent and resistant cell lines reaction. 
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FGF23 also demonstrated a significant difference in expression in A2780CBN and 
A2780CBNDXL cells compared to A2780 parental cells (Figure 9). The microarray 
results showed no amplification in A2780CBN whereas in the QPCR analysis there was a 
significant change of -22.5 fold with a P=0.0065 (Table 5). In addition, A2780DXL cells 
showed no expression in the microarray analysis but the QPCR analysis showed a low 
fold change of -3 with P=0.1299 (Table 5). In A2780CBNDXL cells, both the QPCR and 
the microarry indicated that the resistant cells were down regulated compared to A2780 
parental cell line with a fold change of -13.4 and -11.9 respectively and a P value of 
0.0075 (Table 5). Therefore, both the A270CBN and A2780CBNDXL cell lines 
demonstrated a significant change in the expression of FGF23.  
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Figure 9: QPCR analysis of FGF23 expression in the A2780 parent and 
resistant cell lines. (A) QPCR analysis for FGF23 (B) QPCR for the S28 
control in the A2780 parent and resistant cell lines.  
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The QPCR results for FGFR1b indicated that there was no difference between the A2780 
parental cells and the three resistant cells (Figure 10, Table 5). The microarray analysis 
did not show any expression change in all three resistant cell lines, whereas the QPCR 
analysis illustrated that there was a low fold change of 2.5, -1.8 and -1.5 in A2780CBN, 
A2780DXL and A2780CBNDXL respectively, with P= 0.22, 0.184 and 0,737 (Table 5). 
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Figure 10: QPCR analysis of FGFR1b expression in the A2780 parent and resistant 
cell lines. (A) QPCR analysis for FGFR1b (B) QPCR for the S28 control in the 
A2780 parent and resistant cell lines. 
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The QPCR results for FGFR1c, FGFR2b and FGFR2c indicated that there was not any 
amplification seen in A2780CBN, A2780DXL and A2780CBNDXL resistant cell lines, 
meaning that there was no expression of these receptors in the A2780 cell lines (Figures 
11 A, B, C). 
 
Finally, the QPCR results for FGFR3 showed expression in all the A2780 cell lines but 
there was no difference seen between the A2780 parental cells and all three resistant cell 
lines (Figure 12, Table 5). 
 
Based on the QPCR analyses, FGF18, FGF20 and FGF23 are the most interesting 
changes in FGF expression between the A2780 parent and resistant cell lines.  Therefore, 
the protein expression level of these FGF factors will be validated using western blotting 
technique. As mentioned above, testing FGF18 is important because it involves in 
clusters analysis in two lines which are A2780CBN and A2780CBNDXL. However 
FGF20 is not involved in clusters but it has the biggest change that is present in the 
A2780CBNDXL cell line (-131.53). In addition, FGF23 is well known to be involved in 
epithelial ovarian cancer. 
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Figure 11 A, B, C: QPCR analysis of FGFR1c, FGFR2b and FGFR2c 
expression in the A2780 parent and resistant cell lines. (A) QPCR analysis for 
FGFR1c FGFR2b and FGFR2c. (B) QPCR for the S28 control in the A2780 
parent and resistant cell lines.  
(A) 
(B) 
 
(C) 
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Figure 12: QPCR analysis of FGFR3 expression in the A2780 parent and 
resistant cell lines. (A) QPCR analysis for FGFR3. (B) QPCR for the S28 
control in the A2780 parent and resistant cell lines. 
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Immunoblots to confirm protein expression of FGF factors 
The immunoblots for FGF18, FGF20 and FGF23 were performed using two approaches 
to validate changes in protein expression confirmed by the QPCR analysis. One approach 
involved using cell lysates which would investigate the internal production of FGF 
factors and the second approach was to determine the presence of FGF in the culture 
medium which would investigate the secretion of FGF factors.   
Immunoblots using cell lysates 
The immunoblots for FGF18 were performed using an antibody that was supposed to 
detect FGF18 as a protein at about 23 kDa, which is an appropriate estimated mass for 
FGF18. Although no bands at about 23 kDa could be detected in the immunoblots, there 
was a band visible in the immunoblot at about 20 kDa as well as many non-specific 
bands. The band migrating at the 20 kDa size marker was the best candidate for the 
FGF18 protein (Figure 13A).  Although the expression of FGF18 seems to be lower in 
the A2780CBNDXL cell line compared to the other cell lines, including the A2780 
parent line, densitometry analysis of three biological replicate immunoblots did not 
confirm any significant difference in FGF 18 protein between any of the resistant cell 
lines and the parent A2780 cell line (Figure 13C). The loading control we have chosen 
was beta-actin which has a size of (37 KDa). The density of the beta-actin bands was 
used to normalize the density values of the FGF18 bands. Therefore, the immunoblots for 
FGF18 did not confirm the QPCR result and was not significantly down regulated in 
A2780CBN based on the antibody we have used (FGF18- abcam- ab86571). 
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Figure 13: FGF18 immunoblot of protein lysates from the A2780 parent and 
resistant cell lines.(A)Immunoblot of the FGF18 protein., (B) Immunoblot of the 
beta-actin loading control (C) Densitometry measurement of FGF18 bands 
normalized to the beta-actin controls.  
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The FGF20 immunoblots were performed using an antibody to detect FGF20 at a mass of 
about 24 KDa and were done using cell lysates. While the immunoblots did not show 
FGF20 expression in the region of the 25 kDa marker, there were bands apparent in the 
region between the 25 and 37 kDa markers, migrating closer to 30 kDa marker (Figure 
14A). There was a lack of non-specific bands in the immunoblots generated by this 
antibody, so the one band detected on the immunoblot was assumed to represent the 
FGF20 protein. Densitometry measurement of FGF20 immunoblot bands normalized to 
the beta-actin bands, did not show any significant differences between the parent cell line 
and the three resistance cell lines (Figure 14C). Therefore, the immunoblots for FGF20 
did not confirm the QPCR result in that FGF20 was significantly down regulated in the 
A2780CBN or A2780CBNDXL cell lines based on the antibody we have used (FGF20- 
R&D system- AF2547).  
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Figure 14: FGF20 immunoblot of protein lysates from the A2780 parent and 
resistant cell lines. (A) Immunoblot of the FGF20 protein., (B)Immunoblot of 
the beta-actin protein in the A2780 parent and resistant cell lines.(C) 
Densitometry measurement of FGF20 bands normalized to the beta-actin 
controls. 
  
 60 
The FGF23 immunoblots were performed using an antibody that was supposed to detect 
FGF23 at a mass of about 30-32 kDa. There were numerous non-specific bands in the 
immunoblots but around the 30 to 32 kDa region, a strong band was observed in the 
A2780 parent cell line, which was not seen in A2780CBN resistant cell line but was 
present in the A2780DXL and in the A2780CBNDXL resistant cell lines, although in the 
latter there appeared to be a lighter band (Figure 15A). Based on the mass of the band and 
the expression pattern in the cell lines, this band was assumed to represent the FGF23 
protein. The densitometry measurement of the FGF23 immunoblot bands showed a 
significant reduction in the band density, normalized to beta-actin, in the A2780CBN and 
A2780CBNDXL resistant cell lines compared to the A2780 parent cell line. However, no 
difference was found between the A2780 parent cell line and the A2780DXL cell line in 
terms of FGF23 expression (Figure 15C).  The immunoblots for FGF23 confirmed the 
QPCR result which showed significant downregulation of the FGF23 transcript in the 
A2780CBN and A2780CBNDXL resistant cell lines. 
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Figure 15: FGF23 immunoblot of protein lysates from the A2780 parent and 
resistant cell lines. (A) The FGF23 immunoblot. (B) Immunoblot of the beta-
actin loading control in the A2780 parent and resistant lines (C) Densitometry 
measurement of FGF23 bands, normalized to beta-actin.  
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Immunoblots of culture supernatants 
The FGF growth factors may be secreted and can have a paracrine or endocrine 
distribution. Both FGF18 and FGF20 have paracrine signaling and FGF23 is an 
endocrine factor. Since there is a possibility that the A2780 cell lines could be secreting 
the FGF factors, we decided to investigate if the FGF18, FGF20 and FGF23 factors could 
be detected in the cell culture supernatants and if the levels might be different for the 
resistant cell lines compared to the parent. To analyze the culture supernatants, culture 
medium was concentrated using Amicon centrifugal filter devices with a molecular 
weight cut-off of 50 kDa and 10 kDa. Equal amounts of protein from each concentrated 
culture supernatant were run on SDS-PAGE gels and transferred to membranes for 
immunoblotting. The same antibodies that were used for the cell lysate immunoblots 
were used for the culture supernatant immunoblots. The band patterns were very different 
for the culture supernatants compared to the cell lysates (Figure 16). Based on the 
expected band sizes for FGF18, FGF20 and FGF23, there was no expression of any of the 
three FGF factors observed in the immunoblots (Figure 16). 
  
  
 63 
 
  
Figure16: Culture medium immunoblots for FGF18, FGF20 and FGF23.(A) 
Immunoblot for FGF18. (B) Immunoblot for FGF20. (C) Immunoblot for 
FGF23. 
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In summary, based on these results the immunoblots for FGF18 using cell 
lysate did not confirm the QPCR result and was not significantly down 
regulated in A2780CBN as well as the immunoblots for FGF20 did not confirm 
the QPCR result in that FGF20 was not significantly down regulated in the 
A2780CBN or A2780CBNDXL cell lines. Only FGF23 seems to be promising 
and confirmed the QPCR result which showed significant downregulation of 
the FGF23 transcript in the A2780CBN and A2780CBNDXL resistant cell 
lines. Additionally, immunoblots of culture supernatants did not show any 
expression of the three FGF factors. 
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Small interfering RNA (siRNA) to knockdown FGF23 expression 
 
Based on the western blotting analysis FGF23 was the most interesting changed to 
knockdown, it was significantly down regulated in A2780CBN and A2780CBNDXL. 
To knockdown the promising gene, siRNA experiments was conducted under varying 
conditions. Experimental conditions were derived from the Ambion and 
Lifetechnologies handbook for siRNA and combined with the recommendations from 
the Lipofectamine protocol. These conditions included three transfection controls 
which were lipofectamine to test if Lipofectamine had a negative effect on the cells 
and the negative control-scrambled siRNA, to confirm that any siRNA transfection 
per se does not have a negative effect on the cells. In addition a positive control was 
planned, which was the housekeeping gene GAPDH, which was supposed to show 
that siRNA knockdown can be done successfully. To knock down the expression of 
FGF23, three Stealth siRNA were purchased from Life Technology/Ambion to test if 
single or pooled siRNA transfections will knockdown FGF23.  
 
 The QPCR analysis of GAPDH in A2780 cells that had been transfected 
for 24 hr with a Stealth GAPDH siRNA did not show any knockdown of GAPDH 
expression. There were not any differences between the negative control-scrambled 
siRNA and the three different concentrations for the GAPDH (50nM, 100nM and 
200nM) (Figure 17) (Table 6). 
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Figure 17: QPCR analysis for siRNA transfection for 24 hr GAPDH knockdown.  
Table 6: Fold change values and the P values based on 
the QPCR analysis of the 24 hr GAPDH siRNA 
experiments. The P values are calculated for each QPCR 
analysis comparing GAPDH (50nM, 100nM and 200 
nM) to the negative control-scrambled siRNA.   
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A similar result was observed for the 48 hr transfections, the QPCR did not show any 
significant change between the scrambled negative control and the A2780 cells 
transfected with three different concentrations (50nM, 100nM and 200nM) of the 
GAPDH siRNA (Figure 18) (Table 7). 
 
Block-IT Transfection experiments 
The failure of the GAPDH knockdown experiment lead us to test if the A2780 cells 
were actually taking up siRNA, using lipofectamine in medium with or without 
serum. To do this, a Block-IT test oligo was purchased from Ambion. The Block-IT 
oligo is a nonsense oligo, not targeted to any known gene, and is fluorescently 
labeled. Block-IT oligos can be detected using FITC detection conditions.  
 
 The Block-IT transfection experiments were done using three different 
concentrations (10nM, 50nM and 100nM). We also used two different concentrations 
of lipofectamine which are (5μl and 10μl) to test whether the amount  of 
lipofectamine was adequate, in addition to increasing the incubation times (24 hr, 48 
hr and 72 hr). Of the three incubation times tested, the 48 hr transfection was 
performed in either RPMI with 10% FBS or low serum Optimem. For all 
transfections, the transfection medium containing the siRNA was changed to 
antibiotic-free medium after a 24 hr transfection incubation period (Table 8). 
Transfection efficiency was determined by counting the number of fluorescent cells 
and calculating the ratio between the total number of cells and the fluorescent cells.  
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Figure 18: QPCR analysis for siRNA transfection for 48 hr GAPDH knockdown.  
Table 7: Fold change values and the P values based on 
the QPCR analysis of the 48 hr GAPDH siRNA 
experiments. The P values are calculated for each QPCR 
analysis comparing GAPDH (50nM, 100nM and 200 
nM) to the negative control-scrambled siRNA.   
  
 69 
 
The results for the 24 hr Block-IT transfection did not have high transfection values, 
likely because it was too early for the A2780 cells to show a significant difference in 
fluorescence (Appendix 1). The transfection efficiencies had a range of 50-60 %.  
The 48 hr Block-IT transfection produced reasonable results, which allowed us to 
count cells that had been successfully transfected. The transfection efficiency using 
Optimem in 10 and 50 nM with 5μl lipofectamine was higher than using RPMI with 
10% FBS, also it was higher in 100 nM using 10μl lipofectamine. However, the 72 hr 
Block-IT transfection, A2780 cells were overgrown and was too difficult to count, 
therefore, no transfection efficiency values were calculated for the 72 hr 
transfections. 
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Table 8: Transfection efficiency for the 48 hr Block-IT transfections with varying 
condition. Three different concentrations of Block-IT oligo were used (10 nM, 50 
nM and 100 nM), two different concentrations of Lipofectamine (5μl and 10μl) 
were used and performed two different transfections in either Optimem or RPMI 
containing 10%FBS without antibiotic. 
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After the Block-IT experiments showed what the optimal conditions were for a 
successful transfection, we repeated the 48 hr GAPDH siRNA experiment 
using the optimal conditions from the Block-IT experiments and with fresh, 
newly purchased Stealth siRNA for GAPDH. For example, we used varying 
concentrations of (10 nM, 20 nM and 50 nM) siRNA, we also performed the 
transfections in Optimem and then removed transfection mixture from cells 
after 24 hr and replaced with fresh RPMI and 10%FBS without antibiotic. 
However, no significant difference was seen between the controls and the 
GAPDH. The S28 control QPCR reaction was used in this experiment to 
monitor the experimental conditions (Figure 19) (Table 9).  
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Figure 19: QPCR analysis for siRNA transfection for 48 hr GAPDH knockdown; (A) QPCR 
curves for the controls and the GAPDH with three different concentration (10 nM, 20 nM 
and 50 nM). (B) QPCR curves for the S28 control in the controls and the GAPDH siRNA 
treated samples. 
Table 9: Fold change values and the P values based on the QPCR 
analysis of the GAPDH siRNA experiments. The P values are 
calculated for each QPCR analysis comparing GAPDH (10nM, 20nM 
and 50 nM) to the negative control-scrambled siRNA.  
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After the failure of GAPDH knockdown experiments, we decided to discontinue the 
work with GAPDH siRNA and focus on testing the FGF23 siRNA. There were three 
different stealth FGF23 siRNA purchased from Ambion (HSS 111947, HSS 111948 
and HSS 188481). We set up transfections for each FGF23 siRNA alone, and we also 
combined theFGF23 siRNA in pairs, in addition to setting up one transfection with 
all three FGF23 siRNA pooled. The controls were as before. 
 
Starting with single FGF23 siRNA, there were not any significant changes seen 
between the controls and the single FGF23 siRNA with using 10nM (Figure 20) 
(Table 10). 
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Figure 20: QPCR analysis for siRNA transfection for 48 hr single FGF23 
knockdown. (A) Comparison of the scrambled negative control and the single 
FGF23 siRNA in 10 nM. (B) Shows the S28 control.  
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Table 10: the fold changes values and the P values based on the QPCR 
analysis. The P values are calculated for each QPCR analysis 
comparing single siRNA for FGF23 (10nM, 20nM and 50 nM) to the 
negative control-scrambled siRNA.  
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A similar observation was seen using a higher concentration of 20 nM FGF23 
siRNA, there were no significant changes between the scrambled negative control 
and the three different siRNA (Figure 21) (Table 10). 
 
Finally, with the highest concentration of FGF23 siRNA (50 nM), we still did not see 
any significant different between the scrambled negative control and the FGF23 
siRNA knockdown samples (Figure 22) (Table 10). 
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Figure 21: QPCR analysis for FGF23 siRNA transfection for 48 hr using single 
FGF23 siRNA. (A) QPCR curves for the scrambled negative control and the single 
FGF23 siRNA at a concentration of 20 nM. (B) QPCR curves for the S28 control in 
the control and the FGF23 single knock down samples.  
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Figure 22: QPCR analysis for siRNA transfection for 48 hr single FGF23 
knockdown. (A) QPCR curves for the scrambled negative control and the single 
FGF23 siRNA in 50 nM. (B) QPCR curves for the S28 control in the scrambled 
negative control and the FGF23 siRNA knockdown samples.  
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After that, all possible combinations of the FGF23 siRNAs were combined in 
pooled transfections. The combinations were as follows: (HSS 111947+ HSS 
111948), (HSS 111947+ HSS 188481), (HSS 111948+ HSS 188481) and (HSS 
111947+ HSS 111948+ HSS 188481). Despite combining the FGF23 siRNAs, 
no significant changes were seen between the scrambled negative control and 
the combined FGF23 siRNA samples (Figure 23) (Table 11).  
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Figure 23: QPCR analysis for siRNA transfection for 48 hr pooled FGF23 
knockdown. (A) Comparison of the scrambled negative control and the single 
FGF23 siRNA in 50 nM. (B) Shows the S28 control.  
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Table 11: the fold changes values and the P values based on the QPCR analysis. The P 
values are calculated for each QPCR analysis comparing pooled siRNA for FGF23 (50 
nM) to the negative control-scrambled siRNA.  
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Discussion 
Based on the previous work done by Armstrong et al. and the FIN analysis performed 
by Dr. Kalatskaya of the OICR, there were indications that changes in the expression 
of FGF genes could contribute to the development of resistance to chemotherapy 
drugs in ovarian cancer cells. The hypothesis for the current study was that changes 
in FGF gene expression contributed to the development of resistance to carboplatin, 
docetaxel and combined carboplatin/docetaxel in A2780 ovarian cancer cells. Of the 
FGF genes found to have changes in gene expression in the drug resistant cell lines 
developed by Armstrong et al., QPCR analysis could only show significant changes 
in mRNA transcripts in FGF18, FGF20 and FGF23 in the three resistant cell lines 
compared to the A2780 parent cells. However, we could only confirm a change in 
protein expression for FGF23, which was shown to be altered in A2780CBN and 
A2780CBNDXL cells compared to the A2780 parent cells. Since a change in 
expression could only be shown for the FGF23 gene, siRNA experiments were 
performed to attempt to knockdown its expression in the A2780 parent cell line, in 
order to determine if changing the expression of the FGF23 induce drug resistance in 
the A2780 parent cell line. Unfortunately, the knockdown of FGF23 in the A2780 
cell line was not successful using the siRNA technique, so no firm conclusions can be 
drawn regarding the role of FGF23 in the development of drug resistance in ovarian 
cancer cells. 
 
Numerous studies have reported changes in the expression of FGFs or their receptors 
associated with the development of different types of ovarian cancer. The FGFs can 
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play a role in demethylation of other genes which may lead to the development of 
cancer [77]. However, many of the changes in FGF levels have been observed in the 
high grade serous (HGS) type of ovarian cancer and the A2780 cell line is of the 
endometrioid type. Some of the first studies reported changes in FGF2 (basic FGF) 
expression levels in ovarian tumors [78, 79]. Later studies detected changes in other 
FGF factors, for example FGF1, FGF20, FGF23 and FGFR3 associated with several 
forms of ovarian cancer such as the HGS, endometrioid, and clear cell subtypes [70, 
75, 80-82]. As progress was made in ovarian cancer research, evidence for the 
involvement of FGF factors in response and resistance to chemotherapy was found 
[71, 76, 83-85]. In these studies, several FGF factors and FGF receptors were 
surveyed for expression changes in drug resistant A2780 cell lines, including FGF1, 
FGF2, FGF18, FGF20, FGF23, FGFR1, FGFR2 and FGFR3. Despite the evidence 
for involvement of FGF1, FGF2, FGFR1, FGFR2 and FGFR3 in drug resistance [71, 
76, 84], only transcripts of FGF18, FGF20 and FGF23 were seen to be altered in the 
A2780 resistant cell lines based on the QPCR analysis. This was an expected result 
for FGF20, since it has been shown to be upregulated in the A2780 cell line 
compared to a non-cancerous cell line [86]. FGF18 also is known to be prognostic 
and therapeutic biomarker in epithelial ovarian cancer regards to amplification of 
chromosomal region 5q31-5q35.3 which has been found to predict poor prognosis in 
patients with advanced stage and the overexpression of FGF18 is also a marker that 
promote tumor progression [68]. Therefore, it would be possible to see changes in 
FGF18 since FGF18 makes cancer cells grow faster and the drug resistant cell lines 
are known to grow slower then knocking down FGF18 would slow the growth of 
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cancer cells. However, some FGF factors were seen to be altered in other ovarian 
cancer cell lines but were not seen to be changed in the A2780 cell line for example 
FGF1, FGF2 and FGFR3 were seen to be different in the HGS cell lines [84, 87, 88]. 
FGFR1 also has been shown to be altered in the SKOV3 cell line relative to normal 
cells [76]. Therefore, we would not expect them to necessarily be changed in our 
resistant cell line A2780.  
 
In addition, we would not expect all FGF factors that were identified as having 
altered expression in our drug-resistant cell lines relative to their co-cultured controls 
by microarray analysis to be true changes, because it is known that microarray is not 
high quantitative, in particular for poorly-expressed genes. However, QPCR analysis 
is more accurate since the primers were designed to be specific for the gene 
transcripts. Therefore, it would be possible to see changes in the microarray which 
are not necessarily confirmed by QPCR. For example, QPCR showed a dramatic 
change of the FGF23 transcript in the A2780CBN (-22.5 fold change), however the 
microarray showed no expression. FGF18 also showed upregulation in 
A2780CBNDXL in the microarray results, but the QPCR results showed 
downregulation since the Q-PCR is much more quantitative and has high sensitivity 
and specificity to detect a transcript 
 
The immunoblots for FGF23 using cell lysates confirmed the QPCR results, which 
showed significant downregulation of the FGF23 transcript in the A2780CBN and 
A2780CBNDXL drug-resistant cell lines. It also confirmed the microarray result, 
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which showed a significant downregulation of the FGF23 transcript in 
A2780CBNDXL cells. 
 
The result from the FGF18 immunoblotting experiments did not confirm the QPCR 
results, which showed a downregulation of the FGF18 transcript in the A2780CBN 
cell line relative to A2780 cells, it also did not confirm the microarray result which 
showed an upregulation of the FGF18 transcript in the A2780CBNDXL cell line 
relative to A2780 cells. The FGF18 immunoblots showed many non-specific bands 
but the band that represents FGF18 protein is most likely to be around 20 KDa. 
Densitometry measurements of the FGF18 immunoblot bands normalized to the beta 
actin bands did not show a significant difference in FGF18 protein levels between the 
A2780 parent cells and the three resistant cell lines. Therefore, the protein result did 
not confirm either the microarray or the QPCR result; rather, it showed a very 
different result. We expected to see a downregulation in FGF18 protein levels in 
A2780CBN cells based on our QPCR findings (-8.9); however, these changes were 
not observed in the FGF18 immunoblots. While microarray studies suggested an 
upregulation of about 7- fold in FGF18 transcript levels in A2780CBNDXL cells, 
quantitative PCR findings suggested no change in FGF18 transcript levels in 
A2780CBNDXL cells.  The immunoblot experiments confirm this lack of 
upregulation in A2780CBNDXL cells. Based on the immunoblot anlaysis of the 
FGF18 protein expression in the A2780 and drug resistant cell lines there were no 
significant differences in FGF18 expression in any of the drug resistant cell lines. 
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The FGF20 immunoblots that were performed did not show any bands in the region 
of the 25 KDa marker, which is the molecular weight of FGF20; rather, the bands 
were in the region between the 25 KDa and 37 KDa markers. It is possible that the 
FGF20 protein is post-translationally modified, perhaps by being glycosylated or 
phosphorylated.  This would change the migration of the protein in the gel. Therefore, 
since the position of the FGF20 band is in a different region on the gel but there is 
only one clear band detected on the immunoblot, it is highly possible that this band 
represents the FGF20 protein. Unfortunately, densitometry measurement of FGF20 
immunoblot bands normalized to the beta-actin bands, did not show any significant 
differences in relative FGF20 protein levels between the A2780 parent cell line and 
the three resistance cell lines. This is despite the dramatic changes in FGF20 
expression that we detected by both QPCR and microarray analysis. However, it is 
possible for changes in mRNA levels to not correspond to the protein level due to 
regulation of mRNA levels between transcription and translation.  For example 
natural RNAi can prevent translation of the transcript or alternative splicing can 
generate different transcripts that do not produce protein. 
As a result, we can see mRNA highly upregulated but that does not always reflect the 
protein level. 
 
The FGF18 and FGF20 immunoblots did not confirm either the QPCR or the 
microarray results, however if we had seen a result in protein expression that 
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corresponded to the QPCR or the microarray result that would mean they could play a 
role in drug resistance.  
     FGF18, FGF20 and FGF23 are members of different families, FGF18 is in family 
8 and FGF20 is in family 9. Both families have a paracrine effect in target cells that is 
close to the cells producing the hormones. While FGF20 exhibited a major change in 
gene expression in drug-resistant cells, it is not clear how it could have an effect on 
drug resistance. FGF20 has been found to signal mainly through FGFR2b, FGFR2c, 
and FGFR3c in mouse fibroblasts, through FGFR1c in dopaminergic neurons and 
strongly through FGFR3b in binding assays in BaF3 cells [89-91]. However, in 
A2780 cells, only FGFR1b and FGFR3 were found to be expressed in our study and 
the primers used did not distinguish between isoforms of FGFR3 (Figure 10 and 12). 
Since only FGFR3 was detected in the A2780 cells and this type of signaling has 
been reported in mouse fibroblasts and in a binding assay in BaF3 cells, the 
connection to drug resistance in ovarian cancer is not immediately evident. One 
connection of FGFR3 to acquired resistance in myeloma cells has been reported, 
where a mutation in FGFR3 conferred resistance to FGFR inhibitors [92].   FGF23 
belongs to the FGF19 subfamily which contains the FGF factors with an endocrine 
effect which can enter the blood circulation directly and disperse more than the rest of 
the FGF factors [55], which might have an impact on drug resistance by binding to 
FGF receptors in tumours throughout the body. In contrast to FGF20, FGF23 
activates c-isoform receptors like FGFR1c, FGFR2c, FGFR3c and also FGFR4 [91]. 
Of these only FGFR3 was found to be expressed in A2780 cells, and as mentioned 
before, specific isoforms of FGFR3 were not distinguished in this study.  
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Nevertheless, the expression of FGFR3 does indicate that FGF23 signaling can occur 
in the A2780 cells. To date, the over expression of FGF23 in cancer has been shown 
to be associated with dysregulated serum phosphate levels, usually 
hypophosphatemia [55, 70], and there is no reported evidence of an association of 
FGF23 with drug resistance, other than the role of FGFR3 in acquired resistance to 
FGFR inhibitors as described. Although the signaling by both FGF20 and FGF23 
through isoforms of FGFR3 might indicate a role for FGFR3 in these drug resistant 
cell lines, the report by Chell et al. focuses on loss of inhibition by FGFR inhibitors.  
This is in contast to resistance to carboplatin and combined carboplatin and docetaxel 
in A2780CBN and A2780CBNDXL cells, respectively, where changes in the 
expression of FGF20 and FGF23 occur, which might impact on FGFR3 signaling.  
.However, this does not preclude some other role for signaling through FGFR3 in 
resistance to carboplatin or carboplatin/docetaxel. 
 
Since there is a possibility that the A2780 cell line could secret the FGF factors, we 
attempted to detect FGF secretion into the cell culture medium with the method of 
using Amicon centrifugation devices to concentrate the culture medium, with 
subsequent immunoblotting experiments with antibodies to the three FGFs having 
altered expression in our studies.  None of the immunoblotting experiments were able 
to detect expression one or more of the three FGFs in the medium of our drug-
resistant A2780 cells (Figure 16).  The lack of detection of FGFs in the culture media 
may not be due to a lack of secretion of the factors but due to low levels of secretion 
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of FGFs, which were not adequately concentrated by the centrifugation method in our 
study to detect them. 
 
A knockdown of FGF23 expression was not achieved in our experiments employing 
either the single siRNA against FGF23 or pooled siRNAs against FGF23. No 
significant difference in FGF23 transcript was observed between the A2780 parent 
cells and the three resistant cell lines. Since FGF23 was downregulated in the 
A2780CBN and A2780CBNDXL cell lines based on our immunoblot experiments, 
we would expect to see the A2780 parent cell line acquire resistance to CBN and/or 
DXL, if we had been successful in knocking down FGF23 transcript and protein 
expression in the A2780 cell line. If such a knockdown would have been possible, 
and the A2780 cells acquired resistant to carboplatin and/or DXL, then this would 
confirm FGF23’s important role in carboplatin resistance. 
 
One reason for the unsuccessful knockdown experiments may have been the poor 
level of cell transfection, due to a low transfection efficiency. However, we are fairly 
confident that the transfections were highly successful, given our findings with the 
BLOCK-iT transfection optimization experiments, which showed transfection 
efficiencies as high as 70-85%. Using the same conditions for both the GAPDH and 
FGF23 transfections did not, however, result in a significant knockdown in either 
GAPDH or FGF23 expression. Since it is unlikely that a low transfection efficiency 
was responsible for the lack of gene knockdown, other factors may have caused the 
failure of these experiments. For example, it is possible that the mRNA for FGF23 in 
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the A2780 cells has small genetic variations, which do not allow the siRNAs to bind 
effectively to the mRNA for FGF23. Since the siRNAs are only 21 nucleotides in 
length, any sequence change in the transcript could disrupt the binding of the siRNA.  
Another possibility is that the target for the siRNA, while binding to the transcript, 
did not result in targeted mRNA degradation.  Targeting different areas within the 
transcript might have been needed. 
We also had a similar expectation of induced drug resistance, if we had 
attempted and succeeded in knocking down FGF18 and FGF20 gene expression 
in A2780 cells.  Moreover, if knockdown of all three FGF transcripts had a 
partial effect on drug resistance, then pooling them might have conferred even 
greater drug resistance. 
 
Conclusion 
We have been able to confirm some changes in gene expression from microarray and 
FIN analysis, suggesting a possible role for FGF in drug resistance. However, we 
could only confirm a change in protein expression for one of the FGF factors, which 
had reduced expression in A2780CBN and A2780CBNDXL cells. 
 
Future directions 
Future directions might involve repeating western blots with other antibodies to 
FGF20 and FGF18 (in order to possibly confirm changes in gene expression at the 
protein level).  Repeating the siRNA knock down experiments for FGF23 using other 
siRNAs, targeted to other sites in transcript. CRISPR constructs may also be more 
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ideal for successfully knocking down FGF23 expression.   Depending upon whether 
the future Western blots for FGF18 and FGF20 show consistent changes in protein 
expression in the drug resistant cell lines, then additional siRNA knockdown 
experiments for FGF18 and FGF20 could prove successful in drawing a further link 
between changes in FGF signalling pathways and drug resistance. In addition, it 
would be interesting to screen other data sets such as the Cancer Cell Line 
Encyclopedia (CCLE) to validate the result. This will allow us to identify a role for 
FGF growth factors as therapeutic targets in ovarian cancer. 
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Figure 5 
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Figure 8 
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